Jennifer Nadeau
Primary Care · Beverly Hills, FLNPI 1346891777
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$687
- GSK$405
- Amgen$385
- Boehringer Ingelheim$289
- AstraZeneca$265
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,676100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $1,023 |
| AbbVie | 29 | $687 |
| GSK | 23 | $405 |
| Amgen | 21 | $385 |
| Boehringer Ingelheim | 10 | $289 |
| AstraZeneca | 17 | $265 |
| Bayer | 13 | $242 |
| Lilly USA, LLC | 10 | $138 |
| Johnson & Johnson(2 entities) | 9 | $136 |
| Amarin Pharma, Inc. | 6 | $134 |
| Pfizer | 8 | $130 |
| Novartis | 4 | $76 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Endo USA, Inc. | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| ABC Home Medical Supply, Inc. | 1 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Merck | 2 | $39 |
| Biogen | 2 | $36 |
| Teleflex LLC | 1 | $31 |
| Abbott | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Urovant Sciences Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,690 in reported general payments places this provider in the 90th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 114 | $133,477 |
| OzempicSemaglutide | 36 | $58,386 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $46,585 |
| JardianceEmpagliflozin | 25 | $39,800 |
| EliquisApixaban | 37 | $39,110 |
| RybelsusSemaglutide | 11 | $25,066 |
| XareltoRivaroxaban | 15 | $23,827 |
| MounjaroTirzepatide | 22 | $22,739 |
| JanuviaSitagliptin Phosphate | 14 | $10,760 |
| Pregabalin | 70 | $5,327 |
| Lubiprostone | 14 | $4,272 |
| Tramadol Hcl | 388 | $3,647 |
| Gabapentin | 100 | $2,936 |
| Atorvastatin Calcium | 346 | $2,857 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $2,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $265 | $133,477114 claims |
| Novo NordiskOzempic, Rybelsus | $1,023 | $83,45247 claims |
| GSKTrelegy Ellipta | $405 | $46,58539 claims |
| Boehringer IngelheimJardiance | $289 | $39,80025 claims |
| PfizerEliquis | $130 | $39,11037 claims |
| Johnson & JohnsonXarelto | $136 | $23,82715 claims |
| Lilly USA, LLCMounjaro | $138 | $22,73922 claims |
| MerckJanuvia | $39 | $10,76014 claims |
| Sanofi-aventis U.S. LLCLantus | $44 | $2,19920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 725 primary care providers in Florida.
Other primary care in Beverly Hills
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.